Tenderwize
Wróć do wyszukiwania

Non-exclusive rebate agreement for glatiramer acetate prefilled syringes

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2027 · 307 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Glatirameracetat in der Darreichungsform Fertigspritze (ATC-Code nach WHO: L03AX13)

52/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

52 / 100

Złożoność

58 / 100

Czynniki ryzyka

Structured data marks electronic submission as not allowed, while the notice text says communication and transmission o...

The notice references project-space documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfri...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive rebate agreements under § 130a(8) SGB V for glatiramer acetate in prefilled syringes.
  • Open-house model with participation open to all eligible pharmaceutical companies during the participation period.
Pokaż pełne podsumowanie

Open-house procurement for non-exclusive pharmaceutical rebate agreements on glatiramer acetate prefilled syringes (ATC L03AX13) in Germany. The contract is a supplies framework-type arrangement with unlimited participation during the participation period, no individual negotiations, no exclusivity, and unknown call-off volume. Participation is electronic via DTVP project space, but submission is marked as not allowed in the structured data, which appears inconsistent with the document text and should be clarified. No detailed procurement document text beyond the TED XML notice was provided, so document-based requirements may be incomplete.

Ryzyka

Structured data marks electronic submission as not allowed, while the notice text says communication and transmission o...

The notice references project-space documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfri...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical entrepreneur for the offered medicines under German medicines law, as stated in the notice.

Eligibility

  • Submission of the completed self-declaration on the absence of exclusion grounds under §§ 123, 124 GWB.

Administrative

  • Submission of the Russia sanctions self-declaration for the bidder and any involved company.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive rebate agreement for glatiramer acetate prefilled syringes

Open-house lot for non-exclusive rebate agreements for the pharmaceutical product glatiramer acetate in prefilled syringe form. Scope is supplies of medicinal products in Germany, with participation open to all interested pharmaceutical companies that meet and accept the stated conditions. No exclusivity or guaranteed minimum purchase volume is provided.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Jun 2025 - Jun 2027

Kategoria

Pharmaceutical products

Termin

Deadline Jun 30, 2027

Szczegóły zamówienia

Data publikacji
17 Apr 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
256358-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3